Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029200519> ?p ?o ?g. }
- W2029200519 endingPage "118" @default.
- W2029200519 startingPage "110" @default.
- W2029200519 abstract "New approaches should be sought to treat high-risk acute lymphoblastic leukemia (ALL). Since aberrant DNA methylation plays an important role in leukemogenesis of ALL, it can be targeted by 5-aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation. 5-AZA-CdR is a prodrug that is activated by deoxycytidine kinase (DCK). Leukemic cells lacking DCK are drug-resistant. In a previous phase I study, we reported that 5-AZA-CdR could induce remissions in ALL. However, some patients developed drug-resistance due to deficiency in DCK. These observations aroused our interest in 3-deazauridine (3-DU), a CTP synthetase inhibitor that is effective against leukemic cells deficient in DCK. In this report, we observed that 3-DU enhanced the in vitro antineoplastic action of 5-AZA-CdR on human leukemic cells by increasing its incorporation into DNA. Using an optimized dose-schedule we showed that this combination could cure some mice bearing L1210 leukemia, even in the presence of a subpopulation of drug-resistant (L1210/ARA-C) leukemic cells lacking DCK. 3-DU alone also cured some mice with L1210/ARA-C leukemia. In a pilot study on 3 relapsed patients with advanced ALL, the combination of 5-AZA-CdR and 3-DU produced a marked reduction in leukemic blasts, confirming our preclinical observations. Furthermore, after several treatments with these agents all three patients developed drug-resistance to 5-AZA-CdR as determined by an in vitro drug sensitivity test. In two patients we showed by enzymatic analysis that the drug-resistance was due to deficiency in DCK. Our preclinical and clinical results provide a strong rationale to further investigate the combination of 5-AZA-CdR and 3-DU for the treatment of advanced ALL." @default.
- W2029200519 created "2016-06-24" @default.
- W2029200519 creator A5038157289 @default.
- W2029200519 creator A5055530946 @default.
- W2029200519 creator A5055819358 @default.
- W2029200519 creator A5063128853 @default.
- W2029200519 date "2011-01-01" @default.
- W2029200519 modified "2023-09-30" @default.
- W2029200519 title "3-Deazauridine enhances the antileukemic action of 5-aza-2′-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase" @default.
- W2029200519 cites W1511596951 @default.
- W2029200519 cites W1575135707 @default.
- W2029200519 cites W1965305626 @default.
- W2029200519 cites W1966474816 @default.
- W2029200519 cites W2004405301 @default.
- W2029200519 cites W2018440411 @default.
- W2029200519 cites W2032004540 @default.
- W2029200519 cites W2033883294 @default.
- W2029200519 cites W2034191899 @default.
- W2029200519 cites W2039768402 @default.
- W2029200519 cites W2043296103 @default.
- W2029200519 cites W2053747212 @default.
- W2029200519 cites W2055407460 @default.
- W2029200519 cites W2056754396 @default.
- W2029200519 cites W2068296418 @default.
- W2029200519 cites W2070471476 @default.
- W2029200519 cites W2070685259 @default.
- W2029200519 cites W2076676433 @default.
- W2029200519 cites W2079278462 @default.
- W2029200519 cites W2084021611 @default.
- W2029200519 cites W2088612988 @default.
- W2029200519 cites W2089392942 @default.
- W2029200519 cites W2095343301 @default.
- W2029200519 cites W2105435030 @default.
- W2029200519 cites W2109895173 @default.
- W2029200519 cites W2111064692 @default.
- W2029200519 cites W2115023583 @default.
- W2029200519 cites W2145166916 @default.
- W2029200519 doi "https://doi.org/10.1016/j.leukres.2010.04.014" @default.
- W2029200519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20510451" @default.
- W2029200519 hasPublicationYear "2011" @default.
- W2029200519 type Work @default.
- W2029200519 sameAs 2029200519 @default.
- W2029200519 citedByCount "19" @default.
- W2029200519 countsByYear W20292005192012 @default.
- W2029200519 countsByYear W20292005192013 @default.
- W2029200519 countsByYear W20292005192014 @default.
- W2029200519 countsByYear W20292005192016 @default.
- W2029200519 countsByYear W20292005192017 @default.
- W2029200519 countsByYear W20292005192018 @default.
- W2029200519 countsByYear W20292005192020 @default.
- W2029200519 countsByYear W20292005192021 @default.
- W2029200519 countsByYear W20292005192022 @default.
- W2029200519 countsByYear W20292005192023 @default.
- W2029200519 crossrefType "journal-article" @default.
- W2029200519 hasAuthorship W2029200519A5038157289 @default.
- W2029200519 hasAuthorship W2029200519A5055530946 @default.
- W2029200519 hasAuthorship W2029200519A5055819358 @default.
- W2029200519 hasAuthorship W2029200519A5063128853 @default.
- W2029200519 hasConcept C108215921 @default.
- W2029200519 hasConcept C114851261 @default.
- W2029200519 hasConcept C126322002 @default.
- W2029200519 hasConcept C185592680 @default.
- W2029200519 hasConcept C202751555 @default.
- W2029200519 hasConcept C203014093 @default.
- W2029200519 hasConcept C2776694085 @default.
- W2029200519 hasConcept C2777844706 @default.
- W2029200519 hasConcept C2778041864 @default.
- W2029200519 hasConcept C2778461978 @default.
- W2029200519 hasConcept C2779268695 @default.
- W2029200519 hasConcept C2780035454 @default.
- W2029200519 hasConcept C2780258809 @default.
- W2029200519 hasConcept C502942594 @default.
- W2029200519 hasConcept C54355233 @default.
- W2029200519 hasConcept C55493867 @default.
- W2029200519 hasConcept C71924100 @default.
- W2029200519 hasConcept C86803240 @default.
- W2029200519 hasConcept C98274493 @default.
- W2029200519 hasConceptScore W2029200519C108215921 @default.
- W2029200519 hasConceptScore W2029200519C114851261 @default.
- W2029200519 hasConceptScore W2029200519C126322002 @default.
- W2029200519 hasConceptScore W2029200519C185592680 @default.
- W2029200519 hasConceptScore W2029200519C202751555 @default.
- W2029200519 hasConceptScore W2029200519C203014093 @default.
- W2029200519 hasConceptScore W2029200519C2776694085 @default.
- W2029200519 hasConceptScore W2029200519C2777844706 @default.
- W2029200519 hasConceptScore W2029200519C2778041864 @default.
- W2029200519 hasConceptScore W2029200519C2778461978 @default.
- W2029200519 hasConceptScore W2029200519C2779268695 @default.
- W2029200519 hasConceptScore W2029200519C2780035454 @default.
- W2029200519 hasConceptScore W2029200519C2780258809 @default.
- W2029200519 hasConceptScore W2029200519C502942594 @default.
- W2029200519 hasConceptScore W2029200519C54355233 @default.
- W2029200519 hasConceptScore W2029200519C55493867 @default.
- W2029200519 hasConceptScore W2029200519C71924100 @default.
- W2029200519 hasConceptScore W2029200519C86803240 @default.
- W2029200519 hasConceptScore W2029200519C98274493 @default.
- W2029200519 hasIssue "1" @default.
- W2029200519 hasLocation W20292005191 @default.